Cancer antigen 125 (CA125) is a commonly and initially used tumour biomarker that is enhanced in 80% of females with advanced-stage ovarian cancer 51, and higher level of CA125 usually indicates poor treatment outcomes and prognosis 52. This evidence concerns the gene MUC16 and ovarian cancer.